SK Biopharm gets approval for sleep disorder drug

Home > Business > Industry

print dictionary print

SK Biopharm gets approval for sleep disorder drug

A biopharmaceutical affiliate of Korea’s SK Group said Thursday that it has won sales approval from the U.S. Food and Drug Administration (FDA) for its sleep disorder drug.

The product, named Solriamfetol, is the country’s first indigenous drug for the central nervous system to receive the green light from the FDA, SK Biopharmaceuticals said.

“This FDA approval is the result of SK Biopharm’s efforts to develop new drugs for the central nervous system,” CEO Cho Jeong-woo said in a press release.

Log in to Twitter or Facebook account to connect
with the Korea JoongAng Daily
help-image Social comment?
lock icon

To write comments, please log in to one of the accounts.

Standards Board Policy (0/250자)